KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Receivables (2016 - 2025)

Historic Change in Receivables for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q1 2025 value amounting to -$25.0 million.

  • CRISPR Therapeutics AG's Change in Receivables rose 8750.0% to -$25.0 million in Q1 2025 from the same period last year, while for Dec 2024 it was -$175.0 million, marking a year-over-year decrease of 18750.0%. This contributed to the annual value of -$175.0 million for FY2024, which is 18750.0% down from last year.
  • According to the latest figures from Q1 2025, CRISPR Therapeutics AG's Change in Receivables is -$25.0 million, which was up 8750.0% from $25.0 million recorded in Q4 2024.
  • In the past 5 years, CRISPR Therapeutics AG's Change in Receivables registered a high of $200.0 million during Q4 2023, and its lowest value of -$200.0 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Receivables was -$17000.0 (2022), whereas its average is -$11076.9.
  • The largest annual percentage gain for CRISPR Therapeutics AG's Change in Receivables in the last 5 years was 40826326.53% (2023), contrasted with its biggest fall of 41166470.59% (2023).
  • CRISPR Therapeutics AG's Change in Receivables (Quarter) stood at $153000.0 in 2021, then tumbled by 132.03% to -$49000.0 in 2022, then soared by 408263.27% to $200.0 million in 2023, then tumbled by 87.5% to $25.0 million in 2024, then tumbled by 200.0% to -$25.0 million in 2025.
  • Its Change in Receivables stands at -$25.0 million for Q1 2025, versus $25.0 million for Q4 2024 and -$200.0 million for Q1 2024.